Cure8 research brief
The study tests whether a simple blood-derived index (CRP×NLR) can help identify moderate-to-severe endoscopic inflammation when timely endoscopy is limited in hospitalized UC patients.
Clinicians treating hospitalized ulcerative colitis patients; researchers of IBD biomarkers; adult patients curious about noninvasive inflammation markers.
The retrospective single-center cohort included 107 hospitalized UC patients who had blood sampling within 24 hours of admission and lower endoscopy within 72 hours. IBI correlated with endoscopic severity and was independently associated with MES ≥2 after adjustment.
Discrimination (AUC) for IBI was reasonable (0.83) and was similar to CRP alone and to a combined CRP+NLR model. The authors report an exploratory Youden-derived IBI cutoff (3.65) but emphasize this should be considered exploratory rather than a validated clinical decision threshold.
Single-center retrospective design and exploratory cutoff mean results need external validation before clinical adoption; the abstract-level content summarizes key methods and results but is not a full article review.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
